Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2019; 73(2): 101–125. doi:10.14735/amgh2019101.

Clinical practice guidelines for chronic hepatitis C virus infection

Petr Urbánek Orcid.org  1, Soňa Fraňková Orcid.org  2, Petr Husa3, Jan Šperl Orcid.org  2, Stanislav Plíšek Orcid.org  4, Luděk Rožnovský5, Petr Kümpel Orcid.org  6

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018; 69 (2): 461–511. doi: 10.1016/j. jhep.2018.03.026.
2. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47 (RR-19): 1–39.
3. Castéra L, Sebastiani G, Le Bail B et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52 (2): 191–198. doi: 10.1016/j.jhep.2009.11.008.
4. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2 (3): 161–176. doi: 10.1016/S2468-1253 (16) 30181-9.
5. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 66 (1): 153–194. 10.1016/j.jhep.2016.09.001.
6. Zeuzem S, Foster GR, Wang S et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018; 378 (4): 354–369. doi: 10.1056/NEJMoa1702417.
7. Forns X, Lee SS, Valdes J et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017; 17 (10): 1062–1068. doi: 10.1016/S1473-3099 (17) 30496-6.
8. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889–1898. doi: 10.1056/NEJMoa1402454.
9. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370 (16): 1483–1493. doi: 10.1056/NEJMoa1316366.
10. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370 (20): 1879–1888. doi: 10.1056/NEJMoa1402355.
11. Naggie S, Cooper C, Saag M et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373 (8): 705–713. doi: 10.1056/NEJMoa1501315.
12. Reddy KR, Bourlière M, Sulkowski M et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015; 62 (1): 79–86. doi: 10.1002/hep.27826.
13. Wilson E, Kattakuzhy S, Kwo P et al. Real-world effectiveness of 8 vs 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in Blacks with HCV: a comparative analysis of clinical trials with real-world cohorts. Hepatology 2017; 66: 608A. [online]. Available from: http: //www.natap.org/2017/AASLD/AASLD_133.htm.
14. Kowdley KV, Sundaram V, Jeon CY et al. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology 2017; 65 (4): 1094–1103. doi: 10.1002/hep.29005.
15. Buggisch P, Vermehren J, Mauss S et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol 2018; 68 (4): 663–671. doi: 10.1016/j.jhep.2017.11.009.
16. Zeuzem S, Ghalib R, Reddy KR et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163 (1): 1–13. doi: 10.7326/M15-0785.
17. Rockstroh JK, Nelson M, Katlama C et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE COINFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2 (8): e319–e327. doi: 10.1016/S2352-3018 (15) 00114-9.
18. Kwo P, Gane EJ, Peng CY et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 2017; 152 (1): 164–175, e164. doi: 10.1053/j.gastro.2016.09.045.
19. Wei LJ, Zhdanov K, Burnevich E et al. Efficacy and safety of elbasvir/grazoprevir in treatment-naive patients with chronic HCV GT1, GT4 and GT6 infection (C-CORAL): a Phase III randomized multinational clinical trial. J Hepatol 2017; 66 (1): S529. doi: 10.1016/S0168-8278 (17) 31460-5.
20. Zeuzem S, Serfaty L, Vierling J et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol 2018; 53 (5): 679–688. doi: 10.1007/s00535-018-1429-3.
21. Abergel A, Hezode C, Asselah T et al. High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: interim results of the STREAGER study. J Hepatol 2018; 68 (Suppl 1): S110. doi: 10.1016/S0168-8278 (18) 30437-9.
22. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983–1992. doi: 10.1056/NEJMoa1402338.
23. Dore GJ, Conway B, Luo Y et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials. J Hepatol 2016; 64 (1): 19–28. doi: 10.1016/j.jhep.2015.08.015.
24. Wyles D, Saag M, Viani RM et al. TURQUOISE-I Part 1b: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for hepatitis C virus infection in HIV-1 coinfected patients on darunavir. J Infect Dis 2017; 215 (4): 599–605. doi: 10.1093/infdis/jiw597.
25. Welzel TM, Asselah T, Dumas EO et al. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, Phase 3b trial. Lancet Gastroenterol Hepatol 2017; 2 (7): 494–500. doi: 10.1016/S2468-1253 (17) 30071-7.
26. Agarwal K, Gaeta BG, Lee SS et al. Long-term clinical outcomes in HCV genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: first interim safety and efficacy results from TOPAZ-I. Hepatology 2016; 64: 427. [online]. Dostupné z: http: //www.natap.org/2016/AASLD/AASLD_54.htm.
27. Welzel TM, Isakov V, Trinh R et al. Efficacy and safety of ombitasvir, paritaprevir/ritonavir and dasabuvir without ribavirin in patients with HCV genotype 1b with or without compensated cirrhosis: pooled analysis across 5 clinical trials. J Hepatol 2016; 64 (2): S824. doi: https: //doi.org/10.1016/S0168-8278 (16) 01613-5.
28. Foster GR, Afdhal N, Roberts SK et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373 (27): 2608–2617. doi: 10.1056/NEJMoa1512612.
29. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368 (20): 1878–1887. doi: 10.1056/NEJMoa1214853.
30. Snopková S, Rozsypal H, Aster V et al. Doporučený postup péče o dospělé infikované HIV a postexpoziční profylaxe infekce HIV.  [online]. Dostupné z: https: //www.infekce.cz/ DoporART16.htm.

Credited self-teaching test